China SXT Pharmaceuticals Inc (SXTC) - Net Assets
Based on the latest financial reports, China SXT Pharmaceuticals Inc (SXTC) has net assets worth $29.71 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($34.75 Million) and total liabilities ($5.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SXTC PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $29.71 Million |
| % of Total Assets | 85.48% |
| Annual Growth Rate | 44.62% |
| 5-Year Change | 80.87% |
| 10-Year Change | 1503.51% |
| Growth Volatility | 78.56 |
China SXT Pharmaceuticals Inc - Net Assets Trend (2016–2026)
This chart illustrates how China SXT Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see market value of China SXT Pharmaceuticals Inc.
Annual Net Assets for China SXT Pharmaceuticals Inc (2016–2026)
The table below shows the annual net assets of China SXT Pharmaceuticals Inc from 2016 to 2026. Also explore net asset growth rate of China SXT Pharmaceuticals Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2026-03-31 | $29.71 Million | +92.41% |
| 2025-03-31 | $15.44 Million | +10.83% |
| 2024-03-31 | $13.93 Million | -5.18% |
| 2023-03-31 | $14.69 Million | -10.55% |
| 2022-03-31 | $16.42 Million | +2.90% |
| 2021-03-31 | $15.96 Million | +69.78% |
| 2020-03-31 | $9.40 Million | -15.36% |
| 2019-03-31 | $11.11 Million | +238.06% |
| 2018-03-31 | $3.29 Million | +77.36% |
| 2017-03-31 | $1.85 Million | +149.42% |
| 2016-03-31 | $742.77K | -- |
Equity Component Analysis
This analysis shows how different components contribute to China SXT Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3339232000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (March 2026)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $64.13 Million | 215.86% |
| Other Comprehensive Income | $-197.88K | -0.67% |
| Total Equity | $29.71 Million | 100.00% |
China SXT Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of China SXT Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DCM Financial Services Limited
NSE:DCMFINSERV
|
$1.20 Million |
|
Fjordland Exploration Inc
V:FEX
|
$1.20 Million |
|
FNP Technologies SA
PA:MLFNP
|
$1.20 Million |
|
Prominence Energy Ltd
AU:PRM
|
$1.20 Million |
|
Internet Gold Golden Lines Ltd
TA:IGLD
|
$1.20 Million |
|
KOOL2PLAY S.A. ZY -10
F:8Q8
|
$1.20 Million |
|
XTL Biopharmaceuticals Ltd
F:H2K2
|
$1.19 Million |
|
Eurotex Industries and Exports Limited
NSE:EUROTEXIND
|
$1.19 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in China SXT Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2025 to 2026, total equity changed from 15,439,762 to 29,707,422, a change of 14,267,660 (92.4%).
- Net loss of 6,205,085 reduced equity.
- New share issuances of 14,289,362 increased equity.
- Other comprehensive income increased equity by 877,643.
- Other factors increased equity by 5,305,740.
Equity Change Factors (2025 to 2026)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-6.21 Million | -20.89% |
| Share Issuances | $14.29 Million | +48.1% |
| Other Comprehensive Income | $877.64K | +2.95% |
| Other Changes | $5.31 Million | +17.86% |
| Total Change | $- | 92.41% |
Book Value vs Market Value Analysis
This analysis compares China SXT Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-03-31 | $594.21 | $2.36 | x |
| 2017-03-31 | $156.01 | $2.36 | x |
| 2018-03-31 | $276.70 | $2.36 | x |
| 2019-03-31 | $1080.10 | $2.36 | x |
| 2020-03-31 | $760.38 | $2.36 | x |
| 2021-03-31 | $554.56 | $2.36 | x |
| 2022-03-31 | $394.91 | $2.36 | x |
| 2023-03-31 | $55.03 | $2.36 | x |
| 2024-03-31 | $16.06 | $2.36 | x |
| 2025-03-31 | $38.22 | $2.36 | x |
| 2026-03-31 | $43.71 | $2.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently China SXT Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -20.89%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -578.49%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.17x
- Recent ROE (-20.89%) is below the historical average (-12.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 19.06% | 3.81% | 0.59x | 8.48x | $67.27K |
| 2017 | 63.97% | 24.28% | 0.90x | 2.93x | $999.88K |
| 2018 | 36.14% | 16.92% | 0.92x | 2.33x | $859.00K |
| 2019 | 13.86% | 21.95% | 0.40x | 1.57x | $428.45K |
| 2020 | -109.43% | -199.29% | 0.24x | 2.31x | $-11.23 Million |
| 2021 | -17.22% | -57.52% | 0.14x | 2.16x | $-4.34 Million |
| 2022 | -34.92% | -220.43% | 0.08x | 2.04x | $-7.38 Million |
| 2023 | -40.40% | -301.00% | 0.07x | 2.01x | $-7.40 Million |
| 2024 | -22.24% | -160.67% | 0.08x | 1.66x | $-4.49 Million |
| 2025 | -21.40% | -189.77% | 0.08x | 1.40x | $-4.85 Million |
| 2026 | -20.89% | -578.49% | 0.03x | 1.17x | $-9.18 Million |
Industry Comparison
This section compares China SXT Pharmaceuticals Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $290,420,616
- Average return on equity (ROE) among peers: -51.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| China SXT Pharmaceuticals Inc (SXTC) | $29.71 Million | 19.06% | 0.17x | $1.20 Million |
| Aurora Cannabis Inc (ACB) | $1.08 Million | -29.24% | 0.07x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $140.89 Million | 0.00% | 0.10x | $138.64 Million |
| Akanda Corp (AKAN) | $-3.83 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $-30.58 Million | 0.00% | 0.00x | $241.89 Million |
| Alkermes Plc (ALKS) | $1.11 Billion | -4.33% | 0.82x | $7.72 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $3.58 Billion |
| Amphastar P (AMPH) | $329.25 Million | 3.20% | 0.30x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $896.36 Million | -18.93% | 3.86x | $5.80 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $20.01 Million | -419.73% | 172.53x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $5.00 Million | -54.00% | 0.38x | $279.44 Million |
About China SXT Pharmaceuticals Inc
China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo,… Read more